Literature DB >> 9351500

Cyclo-oxygenase isozymes in mucosal ulcergenic and functional responses following barrier disruption in rat stomachs.

T Hirata1, H Ukawa, H Yamakuni, S Kato, K Takeuchi.   

Abstract

1. We examined the effects of selective and nonselective cyclo-oxygenase (COX) inhibitors on various functional changes in the rat stomach induced by topical application of taurocholate (TC) and investigated the preferential role of COX isozymes in these responses. 2. Rat stomachs mounted in ex vivo chambers were perfused with 50 mM HCl and transmucosal potential difference (p.d.), mucosal blood flow (GMBF), luminal acid loss and luminal levels of prostaglandin E2 (PGE2) were measured before, during and after exposure to 20 mM TC. 3. Mucosal application of TC in control rats caused a reduction in p.d., followed by an increase of luminal acid loss and GMBF, and produced only minimal damage in the mucosa 2 h later. Pretreatment with indomethacin (10 mg kg[-1], s.c.), a nonselective COX-1 and COX-2 inhibitor, attenuated the gastric hyperaemic response caused by TC without affecting p.d. and acid loss, resulting in haemorrhagic lesions in the mucosa. In contrast, selective COX-2 inhibitors, such as NS-398 and nimesulide (10 mg kg[-1], s.c.), had no effect on any of the responses induced by TC and did not cause gross damage in the mucosa. 4. Luminal PGE2 levels were markedly increased during and after exposure to TC and this response was significantly inhibited by indomethacin but not by either NS-398 or nimesulide. The expression of COX-1-mRNA was consistently detected in the gastric mucosa before and after TC treatment, while a faint expression of COX-2-mRNA was detected only 2 h after TC treatment. 5. Both NS-398 and nimesulide significantly suppressed carrageenan-induced rat paw oedema, similar to indomethacin. 6. These results confirmed a mediator role for prostaglandins in the gastric hyperaemic response following TC-induced barrier disruption, and suggest that COX-1 but not COX-2 is a key enzyme in maintaining 'housekeeping' functions in the gastric mucosa under both normal and adverse conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351500      PMCID: PMC1564958          DOI: 10.1038/sj.bjp.0701399

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

1.  Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.

Authors:  Alessandra Gambero; Marta Maróstica; Tagliane Liza Becker; José Pedrazzoli
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

2.  Lack of gastric toxicity of nitric oxide-releasing indomethacin, NCX-530, in experimental animals.

Authors:  K Takeuchi; H Mizoguchi; H Araki; Y Komoike; K Suzuki
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

3.  Effect of lafutidine, a histamine H2-receptor antagonist, on gastric mucosal blood flow and duodenal HCO3- secretion in rats: relation to capsaicin-sensitive afferent neurons.

Authors:  Hiroshi Mimaki; Shigeru Kagawa; Masako Aoi; Shinichi Kato; Tsutumi Satoshi; Kazuhiro Kohama; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

4.  Hepatocyte growth factor expression in dextran sodium sulfate-induced colitis in rats.

Authors:  Cesar F Ortega-Cava; Shunji Ishihara; Kousaku Kawashima; Mohammad A K Rumi; Hideaki Kazumori; Kyoichi Adachi; Yoshikazu Kinoshita
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

5.  Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach.

Authors:  H Ukawa; H Yamakuni; S Kato; K Takeuchi
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

6.  Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.

Authors:  M Yao; E C Lam; C R Kelly; W Zhou; M M Wolfe
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.